Compare LOCO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | ATYR |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.2M | 79.2M |
| IPO Year | 2014 | 2015 |
| Metric | LOCO | ATYR |
|---|---|---|
| Price | $10.71 | $0.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $15.75 | $8.75 |
| AVG Volume (30 Days) | 249.1K | ★ 2.0M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | $190,000.00 |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $1.42 | $18,728.88 |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.29 | $0.64 |
| 52 Week High | $12.65 | $7.29 |
| Indicator | LOCO | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 43.06 |
| Support Level | $10.46 | $0.69 |
| Resistance Level | $11.74 | $0.76 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 21.09 | 29.82 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.